Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.
Hubbeling H, Leithner D, Silverman EA, Flynn J, Devlin S, Shah G, Fregonese B, Wills B, Bedmutha A, Alarcon Tomas A, Parascondola A, Saldia A, Landego I, Hajj C, Boardman AP, Dahi PB, Ghosh A, Giralt S, Lin RJ, Park J, Scordo M, Salles G, Yahalom J, Palomba ML, Schöder H, Perales MA, Shouval R, Imber BS. Hubbeling H, et al. Among authors: salles g. Clin Cancer Res. 2024 Nov 15;30(22):5083-5093. doi: 10.1158/1078-0432.CCR-24-0830. Clin Cancer Res. 2024. PMID: 39259292
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. Czuczman MS, et al. Among authors: salles g. Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. doi: 10.1158/1078-0432.CCR-16-2818. Epub 2017 Apr 5. Clin Cancer Res. 2017. PMID: 28381416 Free PMC article. Clinical Trial.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. Among authors: salles g. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. J Clin Oncol. 2021. PMID: 34170745 Free PMC article. Clinical Trial.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Lin RJ, Owens CN, Drill E, Iannotta A, Oliveros M, Schick DL, Noy A, Gerecitano JF, Drullinsky PR, Caron PC, Kumar A, Matasar MJ, Moskowitz C, Korc-Grodzicki B, Zelenetz AD, Salles GA, Hamlin PA. Lin RJ, et al. Haematologica. 2022 May 1;107(5):1144-1152. doi: 10.3324/haematol.2021.278719. Haematologica. 2022. PMID: 34289656 Free PMC article.
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
Morschhauser F, Ghosh N, Lossos IS, Palomba ML, Mehta A, Casasnovas O, Stevens D, Katakam S, Knapp A, Nielsen T, McCord R, Salles G. Morschhauser F, et al. Among authors: salles g. Blood Cancer J. 2021 Aug 20;11(8):147. doi: 10.1038/s41408-021-00539-8. Blood Cancer J. 2021. PMID: 34417444 Free PMC article. Clinical Trial.
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Zinzani PL, Rodgers T, Marino D, Frezzato M, Barbui AM, Castellino C, Meli E, Fowler NH, Salles G, Feinberg B, Kurukulasuriya NC, Tillmanns S, Parche S, Dey D, Fingerle-Rowson G, Ambarkhane S, Winderlich M, Nowakowski GS. Zinzani PL, et al. Among authors: salles g. Clin Cancer Res. 2021 Nov 15;27(22):6124-6134. doi: 10.1158/1078-0432.CCR-21-1471. Epub 2021 Aug 25. Clin Cancer Res. 2021. PMID: 34433649 Free PMC article.
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Stewart CM, Michaud L, Whiting K, Nakajima R, Nichols C, De Frank S, Hamlin PA Jr, Matasar MJ, Gerecitano JF, Drullinsky P, Hamilton A, Straus D, Horwitz SM, Kumar A, Moskowitz CH, Moskowitz A, Zelenetz AD, Rademaker J, Salles G, Seshan V, Schöder H, Younes A, Tsui DWY, Batlevi CL. Stewart CM, et al. Among authors: salles g. Clin Cancer Res. 2022 Jan 1;28(1):45-56. doi: 10.1158/1078-0432.CCR-21-2183. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615723 Free PMC article. Clinical Trial.
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, Olaide Afuye A, Alperovich A, Anagnostou T, Besser MJ, Batlevi CL, Dahi PB, Devlin SM, Fingrut WB, Giralt SA, Lin RJ, Markel G, Salles G, Sauter CS, Scordo M, Shah GL, Shah N, Scherz-Shouval R, van den Brink M, Perales MA, Palomba ML. Shouval R, et al. Among authors: salles g. J Clin Oncol. 2022 Feb 1;40(4):369-381. doi: 10.1200/JCO.21.02143. Epub 2021 Dec 3. J Clin Oncol. 2022. PMID: 34860572 Free PMC article.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Locke FL, et al. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. N Engl J Med. 2022. PMID: 34891224 Clinical Trial.
908 results